• Avalyn Pharma posted a GAAP net loss of USD 28.9 million in Q2 2026, widening from USD 20.2 million a year earlier.
• R&D expense climbed to USD 24.7 million from USD 17.9 million, driven by AP01 and AP02 trials plus the SAIL extension study.
• G&A expense rose to USD 6.6 million from USD 3.9 million on higher headcount and personnel costs, including stock-based compensation.
• Cash, cash equivalents, and marketable securities totaled USD 413.5 million at June 30, 2026; runway projected into 2029.
• MIST Phase 2b enrollment for AP01 reached 398 patients; topline data expected in the second half of 2027, AURA AP02 readout seen late 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalyn Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120800PRIMZONEFULLFEED9808390) on August 12, 2026, and is solely responsible for the information contained therein.